Investment analysts at StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX - Get Free Report) in a report issued on Friday. The brokerage set a "hold" rating on the stock.
Brooklyn ImmunoTherapeutics Stock Up 2.7%
NYSE:BTX traded up $0.18 on Friday, reaching $6.83. 450,472 shares of the company's stock traded hands, compared to its average volume of 773,657. The stock has a 50-day simple moving average of $6.26 and a 200-day simple moving average of $2.99. Brooklyn ImmunoTherapeutics has a 12 month low of $5.10 and a 12 month high of $8.31. The firm has a market cap of $401.78 million, a PE ratio of -3.01 and a beta of 4.61.
About Brooklyn ImmunoTherapeutics
(
Get Free Report)
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Read More
Before you consider Brooklyn ImmunoTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brooklyn ImmunoTherapeutics wasn't on the list.
While Brooklyn ImmunoTherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
